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 Abstract 
MicroRNAs (miRNAs) are approximately 22 nucleotide endogenous RNA molecules which exert 
their functions by base pairing with messenger RNAs (mRNAs), thereby regulating protein-coding 
gene expression. In eukaryotic cells, miRNAs play important roles in regulating biological 
processes such as proliferation, differentiation, apoptosis, and stem cell self-renewal. MiRNAs are 
encoded by the genome, and more than 1,000 human miRNAs have been identified so far. MiRNAs 
are predicted to target ∼60% of human mRNAs and are expressed in all animal cells. Unique 
expression domains, targets, and gain- and loss-of-function phenotypes of particular miRNAs have 
important implications for directed differentiation of stem cell populations. Many cancers show 
variations in miRNA levels, and more specifically an overall downregulation, when compared to 
their normal counterparts. Therefore, miRNAs may be used as potential therapeutic agents to 
correct aberrant transcript levels found in the signaling pathways of cancer.  This review examines 
the most recent acquisition on the role of miRNAs in regulating the cell cycle, with particular 
emphasis on their effects on cell proliferation and differentiation. The second part explores 
specifically the role of these factors in the physiological regulation of embryonic stem cells, of 
cellular reprogramming and their involvement in the activation of stem cells in adult tissues. In the 
third part, the article discusses some issues that relate to the role of miRNAs in the development of 
neoplastic diseases, focusing on aspects of the genetic and trascriptional alterations that determine  
the beginning and the development of tumor process and looking to emphasize their involvement in 
the activation of adult cancer stem cells . 
Introduction 
 
The discovery on the role of the Lin-4 and Lin-14 genes in temporal control of development in the 
model organism Caenorhabditis elegans rapidly rose the attention of researchers about the role 
played by these small molecules in development and cell differentiation in mammals [1]. In the 
same year, another finding increased the interest for this class of molecules . The Lin-4 gene does 
not encode for any protein but gives rise to a 61-nucleotides (nt) precursor RNA that further 
matures to a more abundant 22-nt transcript. In addition it was reported that the LIN-14 protein 
synthesis is regulated post-transcriptionally and that LIN-14 levels are inversely proportional to 
those of Lin-4 RNA [2]. Sequence analysis revealed that Lin-4 RNA is complementary to the 3’ 
untranslated region (3’-UTR) of the Lin-14 gene, leading to the hypothesis that variations in Lin-14 
expression levels were due to a post-transcriptional interaction with Lin-4. This constituted the 
discovery of the first miRNA and target messenger RNA (mRNA) interaction [1,2]. At the 
beginning of the 21st century the evidence of a correlation between miRNA abundance and human 
disease, and specifically an association between the loss of miR-15 and -16 and the occurrence of 
B-cell leukemia [3], marked the beginning of a new era in cell biology, and permanently changed 
our view of the relationship between gene expression and protein levels. Analysis of the correlation 
between mRNAs and human disease is now expanding to include also those sequences that 
constitutes the remaining  90% of eukaryotic genomes and that generate non-coding RNAs. 
Recently a great interest was aroused when miRNAs were shown to act both as tumor suppressors 
and oncogenes, which promote tumor growth. In addition, aberrant expression of several miRNA 
has been shown in many cancers. More specifically an overall downregulation of this class of 
transcripts was demonstrated in cancer cells when compared to normal tissues [4]. Therefore, a 
potential therapeutic use of miRNAs may correct aberrant transcript levels usually found in the 
signaling pathways of cancer cells, and more importantly of cancer stem cells (CSCs). 
 
Biology of miRNAs 
 
miRNAs are endogenously produced, short RNAs of 21-25 nt that are important regulators of gene 
expression at the post-transcriptional level [5,6,7]. By binding to the 3’-UTR of the target mRNA, 
miRNAs can induce degradation or, more frequently, cause repression of protein translation [8]. 
The biogenesis of miRNAs comprises transcription, processing/maturation and degradation (Fig.1). 
Depending on the genomic location, miRNAs are transcribed differently: intergenic miRNAs are 
transcribed into pri-miRNAs by RNA polymerase II since they contain their own promoter and 
regulatory units [9,10]. Intronic miRNAs are co-transcribed with their host genes from a common 
promoter [11,12]. Pri-miRNAs from intergenic region are capped at the 5’ site (m7G), 
polyadenylated at the 3’ site and further cleaved into pre-miRNA by Drosha/DGCR8 
microprocessor complex, which is minimally composed by the ribonuclease (RNase) III 
endonuclease Drosha and its binding partner DGCR8/Pasha [13,14]. Intronic miRNAs are directly 
cleaved by Drosha/DGCR8 complex into pre-miRNAs without affecting the splicing step of the 
host genes [15,16,17]. 
Precursor miRNAs are then exported from the nucleus to the cytoplasm by exportin 5 and Ran-GTP 
[18,19]. Here they are processed again to generate short (22-25 nt) duplexes (imperfect miRNA 
duplex) by the RNase III Dicer [20], which is part of the pre-miRNA processing complex [21,13]. 
The pre-miRNA, RNase III Dicer and Argonaute 2 (Ago2) form the pre-RISC (RNA-induced 
silencing complex) [22]. One strand of the short RNA duplex is loaded into the Ago2-containing 
RISC [14] to form a miRNA silencing complex, while its complementary (passenger) strand is 
subsequently degraded [23]. The RISC-loaded mature miRNA is protected from degradation by 
Argonaute proteins. However, after finishing its task, the mature single-strand miRNA will also be 
degraded by the 5′-3′ exoribonuclease XRN2 [24] or by 3′-5′ exoribonucleases, like human 
polynucleotide phosphorylase (PNPase) [25] and nuclear exosome [26]. A more complete review of 
the factors or mechanisms that regulate protein stability and degradation of miRNAs have been 
recently summed up [27,28]. In mammals, Ago2 is the only Argonaute family member with 
endonuclease activity [23,29]. Analysis of the mRNAs that co-immunoprecipitate with Dicer 
suggests that Dicer and its associated proteins are not part of the miRNA effector complexes, since 
the Dicer-enriched transcripts share no significant similarity with the miRNA targets 
immunoprecipitated with Ago [22]. Thus, the Ago proteins disengage from the RISC loading 
complex before targeting mRNAs [30]. Nucleotides in the mature miRNA pair with complementary 
sequences in the mRNA which forms a short helix. Complete complementarity between the 20-22 
nt of the small RNA and the mRNA leads to degradation, hence ‘silencing’ of the transcript. In 
contrast, partial base pairing between nucleotides 2-8 of the miRNA (the so called seed sequence) 
and the mRNA leads primarily to suppression of protein translation and partial degradation [31,8]. 
It is still not clear how miRNAs physically find their target mRNAs in the cell, and how do protein-
protein interactions facilitate targeting [32]. The free energy of base pairing drives association of 
the complementary miRNA with its target mRNA [33]; however, it is not known how these two 
nucleic acid strands are brought into close enough proximity to achieve helix formation.  
A number of proteins that have been co-purified with Ago2 could potentially participate in this 
interaction. They include Ago family member (Ago1), several RNA binding proteins such as the 
Fragile X mental retardation protein (FMRP), putative RNA binding proteins like Vasa intronic 
gene (VIG) and an RNA recognition motif-containing protein, Trinucleotide repeat-containing 6B, 
(TNRC6B)[34,35,36]. Mammalian FMRP and its autosomal paralogs, fragile X-related proteins 1 
and 2 (FXR1P and FXR2P) are correlated with Dicer and other components of the RISC, including 
Ago [37]. Phosphorylation of FMRP eliminates association with Dicer and may function as a switch 
for association with the miRNA pathway [38]. Furthermore, FMRP has been demonstrated to 
directly associate with miRNAs in vitro and to specifically pair miRNAs to RNAs containing the 
correct seed sequence [39]. TNRC6B is a member of a family of proteins that are the vertebrate 
paralogs of GW182, a scaffolding protein. GW182 is present in the core miRNA silencing complex 
and it is important for localization to processing bodies, as well as for translation silencing and 
mRNA degradation [40,41]. TNRC6A, -B and -C associate with miRNA-complexed  Ago proteins 
and the TNRC6 proteins contain a P-body localization domain [42]. It has been reported recently 
that GW182 interferes with mRNA circularization and also recruits the deadenylase complex 
through interaction with poly(A) binding protein C1 [43], this evidence support the hypothesis that 
GW182 is involved in miRNA-mediated silencing. 
 
Fig.1  
 
The miRNAs serve as meta-controllers for gene expression and are crucial for the cellular changes 
that are necessary for development. A few hundred miRNAs have been identified in various 
organisms and current estimates indicate that these miRNAs may regulate almost half of protein-
coding genes [44]. Bioinformatics analysis coupled with experimental validation has lead to 
estimate that most animals have a few hundred miRNA coding genes [6,7]. MiRNAs are encoded 
by the genome, and more than 1,000 human miRNAs have been identified so far and are predicted 
to target ∼60% of human mRNAs [45]. By regulating gene expression, miRNAs play critical roles 
in a variety of cellular and physiological activities [46]. In human diseases, miRNA expression is 
frequently altered, thus contributing to the pathogenesis [47,48,49,50,51]. 
miRNAs can modulate cellular response to environment, influencing the differentiation from a 
multipotent progenitor through progressively committed states to a more differentiated condition. 
These properties make miRNAs nearly ubiquitous and fundamental in all tissues. 
 
miRNAs and cell cycle 
 
miRNAs play an evolutionarily conserved developmental role modulating several physiological 
functions. Although they exhibit limited complementarity with their target mRNAs, they regulate 
fundamental processes during embryogenesis and in adult life. In fact, miRNAs participate in all 
biological processes, such as stem cell maintenance, developmental timing, cell proliferation, 
differentiation, apoptosis, signal pathway and pathogenesis [52,53]. A significant role of miRNA in 
the cell-cycle and in maintaining a balance between cell proliferation and apoptosis has been 
reported. This is achieved by influencing the activity of regulatory proteins, such as cyclins, that 
control cell proliferation. In particular, miR-221 and miR-222 promote cell-cycle progression (G1-S 
transition) targeting mRNAs encoding the cyclin-dependent kinase (CDK) inhibitory proteins p57 
and p27 [54,55]. On the other side, miRNAs negatively regulate cell proliferation inducing growth 
arrest by directly decreasing the expression of cyclin/CDK complexes. Cyclin-dependent kinase 6 
(CDK6) expression is inhibited by miR-129 and miR-137 respectively in normal cells [56] and in 
oral squamous carcinoma cells [57]. The same CDK6 and cyclin D1 are under regulation of miR-
34a [58]. Moreover, miRNAs are involved in signalling pathways implicated in the cell-cycle. p53 
is a tumour suppressor activated in response to cellular stress that is able to induce cell-cycle arrest, 
senescence, or apoptosis. miR-34 is transcriptionally activated by p53 and serves as mediator of p53 
signalling pathway [59,60]. miR-192/215 and miR-194 clusters are shown to be p53-responsive and 
can induce cell-cycle arrest by indirectly triggering p21 expression [61,62]. The PI3K/AKT 
signalling pathway plays crucial roles in many cellular processes including cell proliferation, 
differentiation, and motility. Upon PI3K activation, Akt phosphorylates and inhibits the activity of 
protein kinase GSK3b, which stimulates degradation of cyclin D, therefore activation of PI3K 
signalling pathway stabilizes cyclin D and enhances proliferation. This pathway is inhibited by 
phosphatase and tensin homolog (PTEN), which modulates cell-cycle and serves as an important 
tumour suppressor gene [58]. PTEN is fine-tuned by several miRNA, such as miR-17-92 family 
members [63]. 
miRNAs play a role in apoptosis modulation, as expression of several miRNAs can be induced by 
serum starvation, DNA damage [53], and hypoxia [64]. Cells deprived of miRNA regulation by 
Dicer or Ago2 silencing are more susceptible to UV [65]. miR-16 is one of the miRNAs that are 
down-regulated only just 4 hours after UV treatment. miR-16 and miR-21 trigger cell-cycle arrest 
by negatively modulating the expression of Cdc25A, a gene that is involved in both G1/S and G2/M 
arrest, and targeting cyclin D1 and cyclin E [53]; miR-29b is induced during the physiologically 
normal process of neuronal maturation and is able to inhibit apoptosis by targeting several BH3-
only members of the Bcl-2 proapoptotic gene family [66]. 
 miRNA Cell / Tissue Target Function 
let-7 
family 
Lung 
Fibroblast 
 
Muscle cell 
 
Neural Stem Cell 
CDC25A [67,68]  
CDC34 [67,69] 
 
CDK4 [67] 
CDK6 [67] 
Cyclin D1 [70] 
Block or delays in the G1/S 
transition 
Increase in G2/M phase cells 
fraction: cell proliferation 
Induction of apoptosis 
Reduction of  the G1/S 
transition 
Inhibition of  proliferation 
and promotion of cell 
differentiation 
miR-15 
family 
Colon and ovary cancer 
cells 
 
Embryonic Stem cell 
CDC27, CDK6, 
Cyclin D1 [71,72] 
 WEE1 [73] 
Accumulation of cells in 
G0/G1, cell cycle arrest 
Regulation of  the G2/M 
checkpoint 
miR-17 
family  
 
 
 
 
miR-17-92 
cluster 
Umbilical vein endothelial 
cells  
Unrestricted somatic stem 
cells differentiated into 
neuronal lineage 
Choriocarcinoma cell 
 
Glomerular mesangial cells 
Cyclin D1 [74] 
E2F1 [75] 
 
p21Cip1/Waf1 [76] 
 
PTEN [63] 
Arrest of cell cycle at G1/S 
transition 
Promotion of  cell 
proliferation 
 
Cell-cycle progression 
 
Increase of  PIP3 and Akt 
activation 
miR-19a Neural progenitor cells CyclinD1 [77] Neuronal differentiation, cell-
cycle exit 
miR-24 Lung fibroblast cell line  AURKB, CCNA2, 
CDC2, CDK4, E2F2, 
MYC [78] 
Inhibition of cell-cycle 
progression, increase of the 
G1 compartment 
miR-25 Gastric adenocarcinoma and 
corresponding normal tissue 
p57Kip2 [79] Ensure the G1/S transition 
miR-34a/c Non-small cell lung cancer 
A549 cells  
Primary keratinocytes and 
embryonic skin 
CCND1, CDK6 [58] 
CDK4,Cyclin D1 [80] 
G1 cell-cycle arrest  
G1-phase arrest 
miR-124a Medulloblastoma cells CDK6 J [81] Decrease cell proliferation 
miR-129 Mouse lung epithelial cells 
and human lung 
adenocarcinoma cell lines 
CDK6 [56] G1 phase arrest that 
eventually leads to cell death 
miR-137 Oral squamous cell 
carcinoma 
CDK6 [57] Decrease in S and G2/M 
phase cells and induction of  
accumulation of G0/G1 phase 
cells 
miR-149* Neuroblastoma cell line E2F1[82] Induction of  apoptosis 
miR-192/ 
miR-215 
Normal colon tissue p53, CDKN1A/p21[61] Cell cycle arrest 
miR-
221/222 
Hepatocellular carcinoma; 
ovarian carcinoma 
CDKN1B/p27, 
CDKN1C/p57 [54,83] 
Increase of number of cells in 
S-phase 
miR-290 Embryonic stem cells (ESC) WEE1, Fbxl5 [84] Prevention of  ES cells from 
cluster and embryonic carcinoma 
cells (ECC) 
accumulating in G1 phase 
miR-330 Prostate cancer cell E2F1 [85] Induction of apoptosis 
miR-331-
3p 
Gastric cancer E2F1 [86] Block in G1/S transition 
miR-
322/424 
miR-503 
Myoblasts (C2C12) 
differentiating into 
myotubes 
U2OS osteosarcoma cells  
CDC25A [87] Acceleration of  myogenic 
differentiation  
 
Promotion of G1 Arrest 
miR-
449a/b 
 
miR-449 
and  
miR-34 
Breast epithelial and cancer 
cells(MCF-10A, MCF-7); 
Colorectal carcinoma cell 
(HCT116), Osteosarcoma 
cell (SaOS, U2OS) 
CDC25A, CDK6 [88] 
 
CDK6 [89] 
Cell cycle arrest at G1 phase 
 
Cell cycle arrest and 
apoptosis 
 
Table. 1 miRNA and cell cycle function 
 
 
 
miRNAs and tissues specific functions 
 
There are increasing evidences of roles played by miRNAs during cellular differentiation, such as 
targeting negative regulators of genes responsible for the epigenetic profile of precursor cells. The 
maintenance of stem/progenitor cells and their differentiation fate follows a well defined epigenetic 
program. This program is coordinately regulated by DNA methylation, histone modifications, and 
miRNAs [90,91,92]. Neurogenesis and myogenesis represent well-described systems in which the 
genetic program from committed precursors to differentiated cells has been dissected into well 
defined steps, in which miRNAs play important functions in modulating transcriptional regulators 
of  specific genes. 
miRNAs are dynamically regulated during neural development. Expression profiling revealed that 
miRNAs have spatiotemporal and cell-specific expression patterns in the nervous system [93]. The 
expression of some miRNAs is brain-specific, such as miR-9, miR-124 and miR-135, while other 
miRNAs are only enriched in the brain, such as let-7, miR-9* (* = from the opposite arm of the 
miRNA precursor), miR-125 and miR-128 [94]. In neural development miRNAs can be divided 
into cell-specific expression groups: preferentially expressed in neurons (let-7, mir-9, mir-124, mir-
125, mir-128), strongly astrocytic (mir-23, mir-29), implicated in oligodendrocyte differentiation 
(mir-138, mir-219,  mir-338) [95,96,97,98]. Segregation of miRNA populations in different cell 
types and the temporal disparity in the appearance of their primary transcripts and cytoplasmic 
precursors compared with the mature form during cell differentiation could explain which are the 
transcriptional control mechanisms that are essential for the shift from the pluripotent, self-
renewing state to a more committed condition. Although not restricted to the nervous system, let-7 
family members are highly represented in miRNA brain libraries [70]. let-7 is a valid example to 
explain the importance of miRNAs for spatiotemporal and cell-specific expression patterns: mature 
let-7 is lacking in undifferentiated cells, but the processing activity on its precursor increases in 
parallel with neural differentiation. Rybak and colleagues have demonstrated that in embryonic 
stem cells, the pluripotency factor Lin-28 binds the pre-let-7 RNA and inhibits processing by the 
Dicer ribonuclease [99]. In embryonic neural stem cells, Lin-28 is downregulated by mir-125 and 
let-7, allowing processing of pre-let-7 to proceed. Deletion of let-7 or mir-125 activity in embryonic 
neural stem cells leads to upregulation of Lin-28 and loss of pre-let-7 processing activity, 
suggesting the presence of a feedback loop in which let-7, mir-125 and Lin-28 participate in an 
autoregulatory circuit that controls miRNA processing during neural stem cell commitment [99]. 
Detailed functions in neuronal development have been shown also for miR-9 and miR-124, two 
miRNAs specifically expressed in the mammalian nervous system. Similarly to let-7 and Lin-28, 
miR-9 and the nuclear receptor TLX are implicated in a feedback regulatory loop to control neural 
stem cell proliferation and differentiation [100]. TLX is highly expressed in neural stem cells but it 
is repressed upon differentiation; in contrast, the level of the miR-9 mature form is increased upon 
differentiation [100]. miR-124 is the most abundant miRNA in both the embryonic and adult central 
nervous system. The striking upregulation of miR-124 during neuronal differentiation suggests that 
it may have a unique function in this process. Ectopic expression of miR-124 in cultured non-
neuronal cells increased the expression of neuronal genes and inhibited non-neuronal genes [101]. 
This process might be required during early embryonic neurogenesis to ensure that differentiation 
occurs at the correct time and also that the appropriate number of neurons is generated. Finally, 
miR-9* and miR-124 are both required to inhibit BAF53a subunit expression in order to switch the 
chromatin-remodelling complex during neural development and to promote differentiation [102]. 
Mutation of miR-9* and miR-124 recognition sites in the 3’-UTR region lead to persistent 
expression of BAF53a and defective activity-dependent dendritic outgrowth in neurons [102].   
The development of cardiac and skeletal muscle is orchestrated by evolutionarily conserved 
networks of transcription factors that regulate the expression of genes involved in muscle growth, 
differentiation, and contractility. miRNAs have been shown to regulate skeletal myogenesis in 
developing embryos and during adult life [103]. The miRNAs participation in the muscle 
transcriptional program expands the precision and complexity of gene regulation in muscle cells. A 
subset of miRNAs are considered specific to the muscle tissue. The most widely studied are 
members of miR-1/206 and miR-133a/133b families. These miRNAs are either specifically or 
highly expressed in cardiac and skeletal muscle. Interestingly, miRNAs regulate muscle gene 
expression, either in a positive or negative way, by targeting chromatin modifying enzymes. 
Examples of interactions between miRNAs and epigenetic regulators of gene transcription are 
provided by miR-1 that mediates downregulation of Histone Deacetylase 4 (HDAC4), a key 
inhibitor of muscle differentiation and miR-133 that represses the Serum Response Factor (SRF), a 
transcriptional activator that promotes differentiation [104]. Thus, miR-1 and miR-133 seem to have 
antagonistic effects on muscle lineages. MiR-1 promotes differentiation of cardiac progenitors and 
exit from the cell cycle. In contrast, miR-133 inhibits differentiation of skeletal myoblasts and 
maintains them in a proliferative state. The results of many studies in fact, indicate that miR-133 
acts in partial opposition to miR-1, promoting muscle progenitor expansion and preventing terminal 
differentiation [104,105]. This effect may occur, in part, through miR-133 repression of cyclin D2 
which controls differentiation and proliferation of muscle cells [106]. Interestingly, miR-1 and miR-
133 are also important regulators of cardiomyocyte differentiation and heart development 
[105,107]. Other miRNAs participate in a regulatory circuit that facilitates gene program transition 
from proliferation of skeletal muscle satellite cells to primary myoblast differentiation. miR-206 is 
induced by MyoD and Myogenin and promotes muscle differentiation by a positive feedback loop. 
miR-1, miR-206 and miR-486 are up-regulated during satellite cell differentiation while markedly 
decreased during skeletal muscle regeneration [108,109]. All these miRNAs promote muscle 
differentiation by directly targeting and downregulating Pax7 protein and mRNA. Transfecting 
miR-206 or miR-486 independently increased the G1 phase population and decreased the S phase 
population of myoblast cells, indicating that these miRNAs also promote cell cycle quiescence 
[109]. 
  
miRNA Cell / Tissue Target Function in neural 
development 
let-7 Embryonic NSC LIN-28 [99] Promotion of  neuronal lineage 
commitment 
miR-9 Telencephalon 
 
NSC 
Midbrain-hindbrain 
Gsh2, Foxg1 [110] 
 
TLX [100] 
fgf8-1, fgfr-1 [111] 
Control of neural progenitor 
proliferation and differentiation 
Promotion of NSC differentiation 
Maintenance  of organizer 
activity at the midbrain–
hindbrain boundary  
miR-9*  
miR-124 
Neural progenitors BAF53a [102] Switch of neural specific 
chromatin-remodelling complex 
during neural development and 
promote differentiation 
miR-17 SH-SY5Y cell 
(neuroblast) 
BCL2, MEF2D and 
MAP3K12 [112] 
Regulation of neuronal 
differentiation 
miR-23 Oligodendrocyte LMNB1 [113] Oligodendrocyte development 
and myelination 
miR-124 Adult SVZ 
Developing spinal cord 
neurons 
ES cell and P19 cells 
P19 cells 
SOX9 [114] 
SOX9 [115] 
unknown [116] 
(REST/SCP1 [117] 
PTBP1 [101] 
Increased neuron formation  
Regulation of neuroepithelial 
stem cells  
Suppresses dendritic branching 
Proneural activity in developing 
CNS 
Nervous System development 
miR-125b SH-SH5Y cell and 
neural progenitor ReNcell 
VM cell 
Multiple targets [118] Promotion of neuronal 
differentiation 
Promotion of  neurite outgrowth 
miR-128 SH-SH5Y cell and 
neuroblastoma 
glioma "stem-like" cells 
Reelin, DCX [119] 
Bmi-1 [120] 
Decrease in growth, motility and 
invasiveness, blocked self-
renewal 
miR-200 Olfactory progenitor cell Notch and TGFβ  
signaling pathways 
and Foxg1 [121] 
Proper differentiation of olfactory 
progenitor cells 
miR-219 Oligodendrocyte cells Sox6 and Hes5 [122] 
PDGFRalpha, Sox6, 
FoxJ3, ZFP238 [95] 
Promotion of oligodendrocyte 
differentiation 
 
miR-125b 
miR-324-
5p/ 
miR-326  
Medulloblastoma GLI1 and SMO [123] Inhibition of cell growth 
miRNA Cell / Tissue Target Function in muscle 
development 
miR-1 
miR-1-2 
C2C12 cell 
Cardiomyocyte 
HDAC4 [104] 
Hand2 [124] 
Irx5 [107] 
Stimulation of  myoblast 
differentiation 
Regulation of cardiac 
morphogenesis and  
electrical conduction 
miR-1 
and miR-
206 
C2C12 cell Cx43 [125] Promotion of differentiation of 
skeletal muscle 
miR-24 Primary myoblast cells Unknown [126] Induction  of cardiomyocyte 
hypertrophy 
miR26a C2C12 cell Ezh2 [127] Promotion of  myogenesis 
miR-27b Satellite cell PAX3 [128] Promotion of  myogenesis 
miR-125b C2C12 cell and primary 
myoblasts 
IGF-II  Inhibition of  myoblast 
differentiation and muscle 
regeneration 
miR-133a C2C12 cell SRF [104] Increase in myoblast proliferation 
miR-145 Vascular smooth muscle 
cell 
KLF4, CamkIId [129] 
[130] 
Induction of differentiation of 
multipotent neural crest stem 
cells into vascular smooth muscle 
miR-143 
and miR-
145 
Smooth muscle cells KLF4, myocardin 
and Elk-1 [130] 
Promotion of differentiation and 
repress proliferation 
miR-181 C2C12 cell and limb 
muscle precursors 
Hox-A1[131] Pro-differentiation effects 
miR-206 C2C12 cell 
C2C12 cell and satellite 
cells 
Unknown [132] 
TIMP3 [133] 
Promotion of muscle 
differentiation 
miR-206 
and miR-
29 
C2C12 cell and primary 
myoblasts 
HDAC4 [134] Myogenic differentiation 
miR-208 Cardiomyocytes Thrap1, MSTN [135] Hypertrophic growth 
miR-214 C2C12 cell N-ras [136] Myogenic differentiation 
miR-
221/222 
Primary cultures of quail 
myoblasts 
p27 [137] Progression from myoblasts to 
myocytes 
miR-486 Neonatal  cardiomyocytes PTEN, Foxo1[138] Regulation of PI3-kinase/Akt 
signaling 
miR-206 
and miR-
486 
C2C12 cell PAX7 [109] Stimulation of myogenic 
differentiation 
 
 
Table. 2 
miRNA role in the development and function of neuronal and muscle tissues. NSC: Neural Stem 
Cell, NCS Neural Central System; SVZ: sub-ventricular zone. 
 
 miRNA and stem cell biology 
 
The path that stem cells take towards differentiation involves extensive changes in gene expression. 
Genes that are responsible for self-renewal and pluri/multi-potency need to be downregulated, while 
new transcripts are required to specialize in tissue-specific functions. Different epigenetic processes 
act at multiple stages to dramatically change the proteome of a stem cell: chromatin remodeling, 
promoter methylation and post-transcriptional regulations represent tightly controlled checkpoints 
in gene expression along with changes in the transcription factors pool. Such a complex network of 
factors results in the ability of the cell to fine tune the expression of hundreds of genes in a 
coordinated and predetermined manner. 
 
miRNA and embryonic stem cells: from pluripotency to lineage commitment 
Embryonic stem cells (ESCs) are defined by two main characteristics: the ability to self-renew and 
to differentiate in vivo in any cell type of the developing organism. Several transcription factors 
(TFs) have been identified as key regulators in maintaining ESCs in an undifferentiated state. 
Among these TFs a major role is played by Oct4, Sox2 and Nanog, which even possess the 
potential to revert a fully differentiated cell to a pluripotent state [139,140]. Whatever, important 
their role might be, they alone cannot account for the complex and extensive modulations in gene 
expression that are required to maintain pluripotency. 
In order to understand the role that miRNAs play in this context different approaches have been 
adopted. Mouse ESCs in which either Dicer or DGCR8 alleles have been deleted are unable to 
correctly process miRNAs precursors and therefore lack most of the mature miRs [141,142]. Both 
cell lines are viable and show phenotypes that are mostly overlapping. Cell proliferation is slower 
and when cultured in conditions that induce differentiation they do not express differentiation 
markers, downregulate pluripotency related genes or lose the ability to form colonies compared to 
wild type ESCs . A similar behavior has been described for human ESCs in which Drosha or Dicer 
where silenced: interestingly introduction of exogenous miR-195 and miR-372 family members 
partially rescued the phenotype of Dicer knockdown cells [73]. In mouse ESCs a comparable 
phenotype rescue of DGCR8 knockdown was shown when miRNAs belonging to the miR-290, 
miR-302 and miR17-92 clusters where introduced [142]. Collectively members of these families are 
called ESCC (ESC-specific cell cycle-regulating) miRs and noticeably they share a very similar 
seed sequence, suggesting that they regulate a common set of genes. 
Mouse and human ESCs show a peculiar cell cycle in which the G1-S transition occurs very quickly 
due to a permanent inactivation of pRb protein by hyperphosphorylation [143]. Moreover high 
levels of cell cycle activators (like cyclin E/A and cyclin D3) and absence of cell cycle inhibitors 
(like INK4 family members) contribute to a very rapid proliferation of ESCs [144]. Quite 
interestingly both the Dicer and the DGCR8 knockdown ESCs show an increased proportion of 
cells in the G0-G1 phase indicating that the G1-S transition in cell cycle might be a key target for 
specific pluripotency-associated miRNAs. The lack of ESCC miRs relieves the repression on 
Cdkn1a, Rb1, Rbl2 and Lats2. These proteins are inhibitor of the cyclin E-Cdk2 complex and 
therefore of the G1-S transition [145,145]. As these data suggest, these miRNAs are able to promote 
a quicker G1-S transition and represent key players in regulating the particular cell cycle that ESCs 
undergo. However other papers demonstrate that while ESCC miRNAs are involved in proliferation 
control, other families of miRNAs are required to control the differentiation process. Lack of 
specific miRNAs is necessary for maintenance of pluripotency as in the case of Let-7 family. 
Introduction of exogenous Let-7 in DGCR8 knockdown cells recovers the ability of ESCs to 
differentiate by targeting several transcription factors that are known to be associated with 
stemness, like c-Myc, LIN-28 and SALL-4 [146]. Another group adopted an elegant approach to 
determine the function of a family of miRNAs which is expressed in mESCs: the miR-290-295 
cluster is highly expressed in mouse stem cells and share a similar seed sequence. This group 
generated a Dicer1-null ES cell line where endogenous Ago2 was replaced by a myc-epitope tagged 
Ago2 that was catalytically inactivated through point mutations. Introduction of miR-294 in this 
cell line allowed for target mRNA to be trapped by miR294/Ago2-myc complexes: subsequent 
immunoprecipitation and RNA sequencing allowed to identify targets of this miRNA. Moreover the 
same authors show how miR-294 introduction resulted in upregulation of LIN-28 (a pluripotency 
factor) and of several targets of c-Myc [147].  In hESCs the miR-302-367 family is similarly 
involved in the control of differentiation: among their targets are lefty1 and lefty2, which along with 
Nodal are required for differentiation and germ layer specification during embryogenesis [148]. 
Overexpression of miR-302s causes an unbalance between Nodal and lefties protein levels that 
ultimately results in a delayed ESCs differentiation. miR-302 and the transcriptional factors OCT4 
and NR2F2 (COUP-TFII) are linked in a regulatory circuitry that critically regulate both 
pluripotency and differentiation in hESCs. In the undifferentiated state, both OCT4 and the OCT4-
induced miR-302 directly repress NR2F2 at the transcriptional and post-transcriptional level, 
respectively [149]. 
While in the latter case miRNAs were responsible for maintenance of pluripotency, other families 
are upregulated when the cell starts differentiating: this is the case of miR-134, miR-296 and miR-
470 which inhibit the expression of the pluripotency factors Nanog, Oct4 and Sox2 [150] and of 
miR-200c, miR-203 and miR-183 that negatively regulate Sox2 and Klf4 [151]. The same 
mechanism is operating in hESCs, where miR-145 has been demonstrated to be able to block self-
renewal by targeting Oct4, Sox2 and Klf4 [152]. 
 
miRNAs and cell reprogramming 
Reprogramming of a differentiated cell to a pluripotent state has been achieved by introduction of a 
group of exogenous transcription factors [139,140]. As previously described these factors have 
important connections with specific families of miRNAs: not only miRs control expression of TFs, 
but at the same time these TFs have been shown to bind the promoters of several miRNAs families 
[153,154]. These data point to a complex network of both transcription factors and miRNAs that 
regulates pluripotency and hence suggest that several miRNAs may be involved in the 
reprogramming process of differentiated cells. 
Notably introduction in mouse embryonic fibroblasts (MEFs) of Oct4, Sox2, Klf4 and miR-294 (as 
a replacement for c-Myc) resulted in iPSCs colony frequency similar when Oct4, Sox2, Klf4 and c-
Myc were used and 10-fold higher than Oct4, Sox2 and Klf4 alone [155]. Similarly an increase in 
reprogramming efficiency was seen when down-regulation of Let-7 miRNA was obtained by use of 
an antisense inhibitor [146]. More recently, three different clusters of miRNAs (miR-17-92, miR-
106b-25, miR-106a-363) have been described as highly induced during the early phase of 
reprogramming in mouse fibroblasts [156]. In addition miR-93 and miR-106b are able to increase 
the iPS generation efficiency in MEFs when used along with the four reprogramming factors, 
probably by promoting a mesenchymal-to-epithelial transition which has been described as the first 
step in reprogramming [156]. It was also shown that miR-93 and miR-106b target p21 (involved in 
G1/S transition) and Tgfbr2 (a member of the TGF-β signaling pathway): both genes are known to 
decrease reprogramming efficiency and hence their down-regulation by miRNAs has a positive 
effect on iPS generation [157]. Finally it has been reported that mir-302 expression in hES led to 
reprogramming of human hair follicle cells to iPS cells. This reprogramming mechanism acts 
through mir-302-targeted co-suppression of four epigenetic regulators, AOF2 (also known as 
KDM1 or LSD1), AOF1, MECP1-p66 and MECP2 [158]. It has been also reported that expression 
of the miR302/367 cluster rapidly and efficiently reprograms mouse and human somatic cells to an 
iPS state without the requirement for exogenous transcription factors [159]. 
 Another interesting study reports  as  mir-302 is expressed most abundantly in slow-growing hES 
cells and quickly decreases after cell differentiation and proliferation. mir-302 not only function to 
reprogram cancer cells into an ES-like pluripotent state but also to maintain this state under a 
feeder-free culture condition, which may offer a great opportunity for therapeutic intervention since 
this reprogramming method does not require vector-based gene transfer. [160]. Furthermore, miR-
302b and miR-372 repress multiple target genes, with downregulation of individual targets only 
partially recapitulating the total miRNA effects. These targets regulate various cellular processes, 
including cell cycle, epithelial-mesenchymal transition, epigenetic regulation and vesicular 
transport. They also increase the kinetics of mesenchymal-epithelial transition during 
reprogramming and block TGFbeta-induced EMT of human epithelial cells [161].  A very recent 
study shows that it is possible to reprogram mouse and human cells to pluripotency by direct 
transfection of a combination of mir-200c plus mir-302 and mir-369 family miRNAs [162]. 
We may conclude that transcription factor-based cellular reprogramming has opened the way to 
converting somatic cells to a pluripotent state. However this approached has faced so far limitations 
resulting from the requirement for exogenous transcription factors and the relative inefficiency of 
the process. On the contrary, miRNAs may be used as powerful tools to discover novel pathways 
that are involved in cell fate transitions using dedifferentiation of somatic cells to induced 
pluripotent stem cells as a case study [163]. 
 
 
The role of miRNAs in skeletal muscle proliferation and differentiation 
Many miRNAs show a tissue-restricted pattern of expression, where specific subsets are found in 
different tissues with little or no overlap. This might suggest a role of miRNAs in the specification 
of various cell types and therefore in the differentiation process.  
For example, miR-9 and miR-124a have been shown to play a key role in differentiation of neural 
progenitors into neurons and astrocytes [164,165]. Quite interestingly expression of these miRNAs 
is restricted to the neurogenic areas of the mouse brain, suggesting that their expression may 
promote differentiation [166]. In vitro experiments showed how inhibition of miR-9 resulted in 
increased phosphorylation of STAT3 and in an impaired differentiation. On the other hand, 
overexpression of miR-9 or of miR-124a caused a decreased STAT3 phosphorylation associated 
with a limited astrocyte lineage differentiation. 
The skeletal muscle is a very well studied tissue where for the first time the role of miRNAs as 
regulators of gene expression has been described. In this context miRNAs have been shown to be 
involved in lineage determination by promoting the differentiation of myoblast precursors into 
skeletal muscle. Specifically miR-1 and miR-133 seem to have an opposite effect: while miR-1 
promotes very efficiently differentiation of myoblasts, miR-133 causes a myoblast expansion by 
enhancing their proliferation [104]. Interestingly introduction of exogenous miR-1 alone is able to 
shift the gene expression profile of HeLa cells towards skeletal muscle cells [167] and thus 
demonstrate the primary role that this miRNA plays in differentiation. In smooth muscle a similar 
control seem to take place: reports indicate that miR-145 might play a role close to miR-1 in 
skeletal muscle, by inducing differentiation in smooth muscle cells and preventing their 
proliferation [130]. 
Even in the hematopoietic system miRNAs are involved in stem cell homeostasis: miR-125b is 
highly expressed in mouse HSC and downregulated in committed progenitors. Its overexpression in 
mouse HSCs resulted in reduced apoptotic rates that led to an expansion of different subsets of 
hematopoietic stem cells (notably the lymphoid-balanced and the lymphoid-biased subsets) [168]. 
  
miRNA and cancer 
Cancer is characterized by the presence of rapid, uncoordinated cell growth. Deregulated genes, 
usually activated oncogenes and inactivated tumor suppressor genes act as major players in the 
development and spread of this malignancy.  miRNAs can target multiple genes, alterations in the 
amount or sequence of the cell’s miRNome can modify the expression of all target genes. Therefore 
miRNA modulation can lead to enhanced rates of proliferation and/or decreased rates of apoptosis 
and these changes can increase the risk of cancer development over a lifetime. This has led to the 
hypothesis that, similar to the coding genes involved in cancer, upregulated miRNAs (oncomiRs) 
may act as oncogenes and downregulated miRNAs (anti-oncomiRs) may act as tumour suppressors 
[169]. In support to this hypothesis a general decrease in mature miRNAs was observed in different 
human malignancies [170,171]. Moreover, miRNA profiles obtained from tumoral tissues reflected 
the developmental lineage and differentiation state of the tumours, whereas messenger RNA 
profiles were inaccurate [172]. The current knowledge is that miRNAs engage complex interactions 
with the machinery that controls the transcriptome and concurrently target multiple mRNAs. 
Estimates report that miRNAs can potentially regulate up to 60% of the human genome. Thus it is 
difficult to attribute mis-expression of a miRNA to a particular phenotype [173,167]. Another 
difficulty is that some miRNAs function as oncogenes in some cell types and as tumor suppressors 
in others  [174]. Thus the definition of miRNAs as oncogenes or as tumour suppressor genes 
requires an indication of the type of cells in which they act. In order to understand the role of 
miRNAs in the initiation and in the development of cancer gain-of-function and loss-of-function 
experiments are adopted in combination with target prediction analyses. These studies, performed 
through overexpression or knockdown of specific miRNAs in cancer cell lines or mouse models of 
various malignancies, have supported a role for some of these miRNAs in tumorigenesis. Some of 
the oncogenic miRNAs that have been described are: Let-7, the first identified conserved miRNA, 
is an anti-oncomiR that functions as a post-transcriptional gatekeeper of cell proliferation genes, 
such as RAS [175]; the mir-15a-mir-16-1 cluster that has been implicated in leukaemiagenesis 
[176]; miR-10a, which is highly expressed in metastatic breast cancer and positively regulates cell 
migration and invasion [177]; mir-155 that by acting alone in the lymphoid compartment is 
sufficient to cause cancer [178,179]; miR-206, whose expression in human rhabdomyosarcoma cell 
lines blocks tumor growth in mouse xenograft models [180]. A more comprehensive list of 
miRNAs implicated in tumorigenesis is presented in table 3. 
The mechanisms by which miRNAs express their oncogenic potential are similar to those of 
oncogenes and tumor suppressor genes: genomic abnormalities, transcriptional deregulation and 
dysregulation of the processing steps and/or the factors that control them. 
 
Genomic Abnormalities 
Chromosomal abnormalities induce oncogenic actions of miRNAs by altering their expression 
[181]. As mentioned, approximately 50% of all annotated human miRNA genes are located inside 
or close to fragile sites, like regions of loss of heterozygosity, regions of amplification and 
breakpoints associated with cancers [3,182]. Analogously, mice genome shows a strong association 
between the chromosomal location of miRNAs and those of mouse cancer susceptibility loci that 
influence the development of solid tumors [183]. Chromosomal translocation of the miR-17-92 
cluster increases miR-19 expression and drives Notch1 signalling to promote acute T-cell 
lymphoblastic leukemia[184], while amplification of miR-26a has been described in glioblastoma 
[185]. Single nucleotide polimorphisms (SNPs) in miRNA genes may also affect the transcription 
of the primary transcripts, the processing of pri-miRNAs and pre-miRNAs, the stability of the 
mature miRNAs and the miRNAs–mRNAs interactions [186] even in the absence of apparent 
effects on its secondary structure [187]. A germline mutation in pri-miR-16-1 results in low levels 
of mature miRNA expression and has been found in a kindred with familial chronic lymphocytic 
leukaemia (CLL) [182] and in New Zealand black mice that naturally develop a CLL-like disease 
[188]. Another functional miRNA SNP located in the 3’ strand of miR-146a leads to altered 
processing, lower expression of the mature sequence and predisposition to papillary thyroid 
carcinoma [189]. 
mRNAs binding sites for miRNAs can be altered by different mechanisms, such as point mutations, 
translocations or shortening of the 3′-UTR. Point mutations in miRNA targets can both create or 
destroy miRNA binding sites [190,191,192]. Among the 120,000 SNPs in 3′-UTR mRNAs, about 
17% destroy putative conserved or non-conserved miRNA binding sites, and 8.6% create new 
predicted target sites [62]. Abelson et al. provided the demonstration that a mutation in the miR-189 
binding site of SLITRK1 was associated with Tourette’s syndrome [193]. miRNA modifications 
with 3′ deletion/addition, 5′ deletion/addition and internal modifications have recently been 
identified. These altered miRNAs, termed isomiRs, arise from variable cleavage sites for Drosha 
and Dicer1 in the hairpin. Their role in post-transcriptional regulation remains to be elucidated but it 
is postulated that these changes could affect miRNA half-life, subcellular localization and target 
specificity [186]. 
 
Transcriptional deregulation 
A deregulation of miRNA expression can be a result of increased or decreased transcription from 
their respective miRNA genes. miRNAs activity can be altered either by aberrant transcription 
factor activity, by repositioning of other genes close to miRNAs promoters or regulatory regions or 
by relocalization of a miRNA near other regulatory elements [194]. p53 was found to directly 
induce miR-34a/b/c miRNAs and to facilitate pri-miRNA to pre-miRNA processing through 
interaction with p68 and Drosha [195]. The mir-142 gene was found at the breakpoint junction of a 
translocation, which causes an aggressive B cell leukaemia due to strong up-regulation of MYC 
gene. miR-10b miRNA is specifically highly expressed in breast cancer cells regulated by the 
transcription factor Twist [196,177]. 
miRNA expression can also be affected by epigenetic silencing. Silencing of miRNA genes by 
DNA promoter mutation, hypermethylation and/or histone hypoacetylation has also been described 
in solid tumours and in haematological malignancies [197,198,199]. Saito and colleagues first 
showed that miR-127 is downregulated due to promoter hypermethylation in human bladder cancer 
[200] but epigenetic silencing of several miRNAs is a frequent and early event in breast cancer 
[201,202].  
miRNA Cancer type Target or Regulator Function 
Let-7 fam Breast , colon, gastric, hepatocellular 
carcinoma, leiomyoma, lung, 
lymphoma, melanoma, ovarian, prostate 
Caspase 3 [203], CDK6, 
CDC25A [204], HMGA2 
[205],  
KRAS, NRAS [68], 
MYC [206], SOC-1 [203] 
TS 
miR-9 Breast, medulloblastoma, ovarian MYC [207] TS/OG 
miR-10a/b Breast   OG 
miR-15a/16-1 
cluster 
Lymphoma, multiple myeloma,  
pituitary adenoma, prostate, pancreatic  
BCL-2 [176], MCL1 [176], 
p53 [60] 
TS 
miR-17-92 
fam 
Breast, colon, gastric, lung 122, 
lymphoma, myeloma, medulloblastoma, 
prostate 
AIB1[208], BIM, CDKN1A 
[209,210], E2F [209], MYC 
[211,209], PTEN [210] 
OG 
miR-21 Breast, cholangiocarcinoma, gastric, 
glioblastoma, lymphoma, lung,  
myelom,  prostat, colon 
PDCD4 [212], GF1alfa [213], 
IL-6 [214], MASPIN [215], 
PTEN [216], TPM1 [217],  
OG 
miR-22/25 Prostate PTEN [218] OG 
miR-26a Glioblastoma,  liver, lymphoma,  
thyroid 
EZH2 [219], MYC [194] TS/OG 
miR-29a/b/c Breast, cholangiocarcinoma, 
epatocarcinoma, lung, lymphoma 
rhabdomyosarcoma 
CDK6 [181]; MCL1 [220]; 
TCL1, DNMT1 [181] 
DNMT3α/β [221]; MYC [194] 
TS 
miR-34a/b/c Breast , bladder cancer, colon, gastric, 
hepatocellular carcinoma, kidney,  
lymphoma; lung, melanoma, 
neuroblastoma, pancreatic, prastate  
BCL2 [222]; CCND1, 
CDK6 [58]; CD44 [223]; 
CREB [224]; FOXP1 [225]; 
MET [226], MYC [222,225]; 
TS 
p53 [59]; SIRT1 [227]; 
ZAP70 [228] 
miR-103/107 Pancreatic   OG 
miR-126 Breast   TS 
miR-128 Glioblastoma   TS 
miR-130 Hepatocellular carcinoma   
miR-141/200 
fam 
Bladder , breast, gastric,  lung,  ovarian,  
renal  
E-CADHERIN [229], 
SUZ12 [230] 
TS/OG 
miR-143/145 Colon, osteosarcoma,  pancreatic  MMP [231]; RAS [232] TS 
miR-155 Breast, colon, lung,  lymphoma, 
pancreatic  
NF-kB [233], CEBPB and 
SHIP1 [234] 
OG/TS 
miR-181a/b/c Glioblastoma, hepatocellular carcinoma  RASSF1A, TIMP3 [203] TS 
miR-205 Prostate, bladder,  breast, oesophageal, 
ovarian, lung, melanoma  
E2F1 [235] TS/OG 
miR-206 Breast, rhabdomyosarcoma  TP53INP1 [236] TS 
miR-221-222 Glioblastoma,  liver  P27(KIP1) [237] OG 
miR-302 Prostate PTEN [218] OG 
miR-340 Breast  MET [238] TS 
miR-335 Breast  SOX4, TNC [239] TS 
miR-371/373 Breast, testicular , thyroid LATS2 [240] OG 
 
Table 3. A list of miRNAs implicated in tumourigenesis. TS = tumor suppressor, OG = oncogene 
Dysregulation of the miRNAs processing steps  
Aberrant miRNA expression in cancer may also result from downstream miRNA processing with a 
decrease in pri- to pre-miRNA conversion, which may affect the composition and total pool of 
mature miRNAs. The global repression of miRNA maturation promotes cellular transformation and 
tumorigenesis. Cancer cells expressing short hairpin RNAs targeting three different components of 
the miRNA processing machinery (Drosha, DGCR8 and Dicer1) showed a substantial decrease in 
steady-state miRNA levels and a more pronounced transformed phenotype [241]. p53 mutants have 
been shown to affect the interaction between p68/p72 and Drosha required for efficient maturation 
of a subset of miRNAs [195] while RNA helicases DDX5 and DDX17 act as a scaffold and 
recruiting factors to the Drosha complex and promote pri-miRNA processing [242]. Also oncogenic 
SMADs, signal transducers of the TGF-β pathway, control Drosha-mediated  miRNA maturation 
through interaction with DDX5 [243]. Finally, Dicer1 and transactivation-responsive RNA binding 
protein (TRBP) mediate pre-miRNA processing. A recent study has found that TRBP is a 
phosphoprotein whose phosphorylation is dependent on kinases of the MAPK/Erk pathway. 
Stimulation/inhibition of MAPK-mediated activation of TRBP enhances/reduces pre-miRNA 
processing and leads to an increase/decrease in cell proliferation [244]. 
A novel paradigm in tumor biology suggests that cancer growth is driven by stem-like cells within a 
tumor, called tumor-initiating cells (TICs) or cancer stem cells (CSCs) that are structurally and 
functionally distinct from the other cells of the tumor mass [245]. Although CSCs are challenging 
to study because they represent a small fraction of the tumor and they rapidly differentiate when 
cultured in vitro, these cells can be isolated based on expression of specific cell surface markers 
[246]. Isolation of CSCs coupled with miRNAs expression analysis shows that some miRNAs are 
upregulated or downregulated in TICs. Neveu and colleagues showed that a subset of 11 miRNAs 
can be used to classify cancer, stem cells and differentiated cells [247]. TICs within specific tumors 
have an altered miRNA expression profile able to modify tumor growth, spread or resistance to 
chemotherapeutic agents. For example miR-200b expression suppresses tumor growth and prolongs 
remission in mouse xenografts and its transcriptional signature is observed in metastatic breast 
tumors [230] while Let-7 and miR-181 family members are up-regulated in hepatocellular cancer 
stem cells and inhibition of Let-7 and silencing of miR-181 leads to an increase in chemosensitivity 
and reduction in motility and invasion [203]. In hepatocellular carcinomas TICs overexpression of 
miR-130b increases resistance to chemotherapeutic agents, enhances tumorigenicity in vivo, and 
gives greater potential for self renewal [236]. Finally, miR-34a, is underexpressed in prostate cancer 
stem cells and its forced expression inhibits clonogenic expansion, tumor regeneration, and 
metastasis while miR-34a antagomirs promote tumor development and metastasis [223]. 
Several difficulties arise when trying to connect altered miRNA network data to tumor initiation, 
growth and spread. First, patient samples are usually collected at a time in which a tumour is 
already well established, therefore analysis of these samples cannot unravel early changes important 
for tumour development. Second, tissues are composed of sub-populations made by different cell 
types, each expressing a distinct gene/miRNA expression signature [169]. Cancer alters both the 
expression programme of the affected tissue but also its cell type composition. In order to 
understand if an altered expression profile is important for various tumor characteristics, it will be 
useful to profile individual tumor cell types that may be present in a tumor sample, as well as define 
miRNAs cellular localization. Third, the currently used target prediction databases [5] do not 
always produce identical reports and necessitate the selection of a few targets for further study and 
validation to be prioritized from a list of hundreds. This choice is made by the researcher and it is 
based on a knowledge of target molecules potentially involved in the malignancy. Finally, although 
abundant miRNAs that regulate oncogene or tumor suppressor genes have the most significant 
oncogenic potential [31], miRNAs that have lower expression can, when acting in combination, 
fine-tune target expression of a given mRNA [248,76]. Therefore, the interplay between miRNAs 
expressed in a particular cell, the expression levels of their targets, and post-transcriptional gene 
regulatory mechanisms must all be taken into account to understand the complex regulatory 
mechanism of miRNA. 
 
 
 
Conclusions 
miRNAs regulate the expression of more than half of all genes. They are being examined for their 
regulatory roles in self-renewal, proliferation, and differentiation of normal and cancer cells. 
Dysregulation of miRNAs and cancer diseases have been put in evidence. The marked enthusiasm 
for miRNAs as a novel class of functional regulators of tissue maintenance and stress response has 
possibly further increased since miRNAs have been shown to be critical for both stem cell 
development and cancer pathogenesis. They may provide new approaches to facilitate the 
knockdown of expression of genes in different ES cell populations and provide new insights in our 
understanding of “stemness”. Many researchers think that the power of RNAi-based approaches can 
be applied for understanding ES cell gene function and may serve to establish foundations in ES 
cell-based therapies. On the other hand, global inhibition of miRNA processing increased 
tumorigenicity and transformation, which suggests their important regulatory role in maintaining 
homeostasis. miRNAs have been shown to act both as tumor suppressors, which help regulate 
growth, and oncogenes, which promote rapid and uncontrolled growth. In addition, many cancer- 
associated regions of the genome contain miRNA genes. Certain cancers have specific miRNA 
profiles (i.e., upregulation or downregulation of certain miRNAs) as well as specific surface 
markers that can be used to associate a particular phenotype to miRNAs dysregulation. This 
knowledge might enable development of novel therapeutic approaches targeted to cancer cells, 
including cancer stem cells. However more functional studies about the role played by specific 
miRNAs within different cancer cells, and particularly CSCs, are needed to identify targets and 
develop effective and safe therapeutic agents. 
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Legend 
 
Fig.1  miRNA biogenesis . The introns from full-length miRNA transcripts are excised to form pri-
miRNA, which then undergoes Drosha processing. The DGCR8 acts as a molecular marker for 
Drosha cleavage by binding to the pri-miRNA at the single-stranded regions . After Drosha 
cleavage, the pre-miRNA is exported from the nucleus into the cytoplasm by Exportin-5 or RAN 
GTP and it is the processed by Dicer into the mature miRNA.  After RISC incorporation, miRNAs 
either inhibit translation or promote degradation of their target mRNA transcripts, depending on the 
degree of complementarity. 
 
